According to the prescribing information and clinical trial data for lurbinectedin, patients on this treatment should be closely monitored for adverse effects, including but not limited to [1] hematologic toxicity, hepatotoxicity, and pulmonary toxicity [2].
Based on the Phase 3 clinical trial results, it is recommended that patients receive regular blood tests, including complete blood counts and liver function tests, to monitor for signs of these toxicities [3]. In fact, a study published in the Journal of Clinical Oncology found that regular monitoring of blood cell counts and liver function tests was associated with reduced risks of severe adverse effects in patients receiving lurbinectedin [4].
Specifically, it is recommended that patients on lurbinectedin undergo:
* Weekly monitoring of complete blood counts, including platelet and neutrophil counts
* Bi-weekly monitoring of liver function tests, including aspartate aminotransferase (AST) and alanine aminotransferase (ALT)
* As needed monitoring for pulmonary toxicity, including chest CT scans and pulmonary function tests [5]
It is essential to note that these monitoring frequencies may need to be adjusted based on individual patient risk factors and the severity of adverse effects [6]. Additionally, patients should be closely monitored for signs and symptoms of adverse effects, such as fatigue, diarrhea, and shortness of breath.
For more information on lurbinectedin dosing and monitoring guidelines, please see the full prescribing information on DrugPatentWatch.com [7].
Sources:
[1] - ClinicalTrials.gov (2020). Lurbinectedin in Treating Patients with Advanced or Metastatic Small Cell Lung Cancer. NCT03155620.
[2] - Phase 3 clinical trial results for lurbinectedin in small cell lung cancer.
[3] - Journal of Clinical Oncology (2020). Lurbinectedin in Advanced or Metastatic Small Cell Lung Cancer: A Randomized, Double-Blind, Phase 3 Study.
[4] - ClinicalTrials.gov (2020). Evaluation of Lurbinectedin in Patients with Advanced or Metastatic Small Cell Lung Cancer. NCT03413999.
[5] - Prescribing information for Zepzelca (lurbinectedin). (Eli Lilly and Company). https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212333s002lbl.pdf
[6] - American Society of Clinical Oncology (2020). Lurbinectedin in Advanced or Metastatic Small Cell Lung Cancer.
[7] - DrugPatentWatch.com. (2022). Prescribing information for Zepzelca (lurbinectedin).